High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma
A recent study demonstrates that the T-cell immunoglobulin and ITIM domain (TIGIT) is the most frequently expressed inhibitory checkpoint receptor on CD8+ T-cells in MM patients. This suggests that TIGIT may play a central role in the immune evasion of malignant plasma cells.
